Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
- PMID: 30814058
- PMCID: PMC6418500
- DOI: 10.1182/bloodadvances.2018025429
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
Abstract
TXA is an active-site inhibitor of uPA.
TXA attenuates MDA-MB-231 BAG cell migration and inhibits endogenous uPA activity.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures
References
-
- Law RH, Abu-Ssaydeh D, Whisstock JC. New insights into the structure and function of the plasminogen/plasmin system. Curr Opin Struct Biol. 2013;23(6):836-841. - PubMed
-
- Law RH, Caradoc-Davies T, Cowieson N, et al. . The x-ray crystal structure of full-length human plasminogen. Cell Reports. 2012;1(3):185-190. - PubMed
-
- Markus G, Priore RL, Wissler FC. The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. J Biol Chem. 1979;254(4):1211-1216. - PubMed
-
- Godier A, Parmar K, Manandhar K, Hunt BJ. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis. J Clin Pathol 2017;70(2):154-161. - PubMed
-
- Fergusson DA, Hébert PC, Mazer CD, et al. ; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-2331. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
